Company Profile

Senti Biosciences Inc (AKA: Senti Bio)
Profile last edited on: 10/26/2023      CAGE: 7N7E1      UEI: FDEFJM4MKC63

Business Identifier: Programmable biology platform for cancer therapies
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2 Corporate Drive First Floor
South San Francisco, CA 94080
   (650) 239-2030
Location: Single
Congr. District: 15
County: San Mateo

Public Profile

An Alumni of JLABS South San Francisco, Senti is organized around addressing the field of Hematologic Malignancies. With a assembled team of engineers and scientists, the effort is usefully described as that of leveraging synthetic biology to treat the most pressing diseases. Principals of the firm suggest that cancer and autoimmune diseases - by definition, inherently complex diseases -- require innovative, more intelligent medicines that have therapeutic effect but - usefully - also include being able to sense cues in the disease environment and respond to these cues in a regulated manner. Describing what they do as "outsmarting complex diseases with more intelligent medicines" the firm’s proprietary synthetic biology platform is structured to provide fundamental advantages for therapeutics development to enable design of adaptive therapies for challenging diseases - a gene circuit repertoire that can be used to create more effective, better tolerated cell and gene therapies that can respond to such factors as disease severity and changes in the microenvironment.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 2 NIH $1,999,994
Project Title: Synthetic Biology Gene Circuits for Cancer Therapy
2018 1 NIH $225,000
Project Title: Engineering Cell Therapies to Treat Inflammatory Bowel Disease (IBD)
2018 1 NSF $225,000
Project Title: An Engineering Platform for Adaptive Medicines

Key People / Management

  Timothy K Lu -- Co-founder and CEO

  Susan D Berland -- Senior Financial Executive & Independent Director

  James J Collins -- Scientific Co-Founder

  Martin A Giedlin -- Senior Vice President Of Science Development

  Curt Herberts -- Chief Financial Officer and Chief Business Officer

  Jose Iglesias -- Chief Medical Advisor

  Susan Kahlert -- Controller

  Brett Kiedaisch -- Associate Director, Analytical Development

  Deborah A Knobelman -- Chief Financial Officer

  Gary Lee -- Chief Scientific Officer

  Philip Lee -- Co-founder and COO

  Dee Olomajeye

  Kanya Rajangam -- Head of Research & Development and Chief Medical Officer

  Mike Rhee -- Senior Vice President Of Legal Affairs

  Wilson Wong -- Scientific Co-Founder